Keywords
COVID-19, tacrolimus, heart transplantation, Paxlovid, phenytoin
Abstract
Tacrolimus is commonly used as a prophylactic against acute rejection in transplant patients. Tacrolimus toxicity has numerous presentations that have been well documented in the literature and can be induced by a wide variety of agents. We present a novel case of tacrolimus toxicity in a cardiac transplant patient induced by outpatient treatment for COVID-19 pneumonia with ritonavir-nirmatrelvir, which was successfully treated with phenytoin therapy.
References

Views: 772
HTML downloads: 384
PDF downloads: 523
Published:
2022-09-16
Issue:
2022: Vol 9 No 9
(view)